From OT Europe

Grünenthal, KU Leuven collaborate to develop novel, non-opioid pain treatment

Grünenthal, the Katholieke University Leuven’s Center for Drug Design and Discovery, and the Laboratory of Ion Channel Research announced a research collaboration to develop novel, non-opioid drug candidates to treat painful diseases with unmet medical needs, according to a press release.

According to the release, the collaboration builds on lead compounds created by the groups and by Thomas Voets and Joris Vriens, who identified a potential target for non-opioid pain management. Grünenthal will offer its technical capabilities in pain research and drug development to progress the compounds toward first-in-class clinical candidates.

“We are delighted to be part of this collaboration,” Klaus-Dieter Langner, chief scientific officer of Grünenthal, said in the release. “It is a perfect example of an integrated approach that comprises the capabilities of the academic environment, early drug discovery centers and the pharmaceutical industry to deliver innovative solutions for unmet patient needs. To leverage the latest approaches in pain research, Grünenthal is strongly committed to initiate close collaborations with the scientific community on early-stage [research and development] R&D projects.”

Reference:

www.grunenthak.com

Grünenthal, the Katholieke University Leuven’s Center for Drug Design and Discovery, and the Laboratory of Ion Channel Research announced a research collaboration to develop novel, non-opioid drug candidates to treat painful diseases with unmet medical needs, according to a press release.

According to the release, the collaboration builds on lead compounds created by the groups and by Thomas Voets and Joris Vriens, who identified a potential target for non-opioid pain management. Grünenthal will offer its technical capabilities in pain research and drug development to progress the compounds toward first-in-class clinical candidates.

“We are delighted to be part of this collaboration,” Klaus-Dieter Langner, chief scientific officer of Grünenthal, said in the release. “It is a perfect example of an integrated approach that comprises the capabilities of the academic environment, early drug discovery centers and the pharmaceutical industry to deliver innovative solutions for unmet patient needs. To leverage the latest approaches in pain research, Grünenthal is strongly committed to initiate close collaborations with the scientific community on early-stage [research and development] R&D projects.”

Reference:

www.grunenthak.com